Showing results (281-290 of 293) with videos related to

Sort By:
Pageof 30
Bioorganic & Medicinal Chemistry Letters|March 7, 2012
Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitorJared N Cumming, Elizabeth M Smith, Lingyan Wang, et al.
Bioorganic & Medicinal Chemistry Letters|June 29, 2010
T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones-optimization, design and synthesisElizabeth M Smith, Steve Sorota, Hyunjin M Kim, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2012
Structure activity relationship studies of tricyclic bispyran sulfone γ-secretase inhibitorsWen-Lian Wu, Theodros Asberom, Thomas Bara, et al.
Bioorganic & Medicinal Chemistry Letters|October 24, 2006
2,6-Disubstituted N-arylsulfonyl piperidines as gamma-secretase inhibitorsDmitri A Pissarnitski, Theodros Asberom, Thomas A Bara, et al.
Bioorganic & Medicinal Chemistry Letters|August 31, 2001
Metabolic stabilization of benzylidene ketal M(2) muscarinic receptor antagonists via halonaphthoic acid substitutionC D Boyle, S Chackalamannil, J W Clader, et al.
Acta Neuropathologica|January 17, 2024
Large-scale validation of skin prion seeding activity as a biomarker for diagnosis of prion diseasesWeiguanliu Zhang, Christina D Orrú, Aaron Foutz, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of DyslipidemiaAnandan Palani, Ashwin U Rao, Xiao Chen, et al.
Journal of Medicinal Chemistry|March 29, 2022
Lead Optimization to Advance Protease-Activated Receptor-1 Antagonists in Early DiscoveryMihirbaran Mandal, Maria Madeira, Rupesh P Amin, et al.
ACS Medicinal Chemistry Letters|February 16, 2013
Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ ReductionAndrew W Stamford, Jack D Scott, Sarah W Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 19, 2001
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoJ M Strizki, S Xu, N E Wagner, et al.
Pageof 30